Maternal immune response to UTI, not bacteria, drives preterm birth risk

For decades, doctors have known that urinary tract infections during pregnancy carry a serious risk: babies born too early. More than a million infants die each year from complications of preterm birth, making it the leading cause of infant mortality worldwide. Yet the mechanism behind this connection has remained murky. A team at Baylor College of Medicine set out to understand why a bladder infection could trigger labor weeks before a baby is ready to be born, and what they discovered upends the conventional assumption about what actually causes the harm.

The culprit is not the bacteria itself. It is the mother's immune system's response to the bacteria—specifically, an excessive inflammatory reaction in the bladder and an imbalance in immune signaling molecules called cytokines. Researchers led by Dr. Kathryn A. Patras, an associate professor of molecular virology and microbiology at Baylor, published their findings in Science Translational Medicine after conducting experiments in mice that, remarkably, reproduced the same pattern of preterm birth seen in human pregnancies. The discovery opens a new avenue for intervention: if the immune response, not the infection itself, drives early labor, then modulating that response might prevent it.

The team built a mouse model of maternal urinary tract infection and tracked what happened during pregnancy. The results were striking. Only about half of the pregnant mice developed preterm labor and birth after infection—a finding that immediately suggested the bacteria alone could not be the whole story. If the bacterial infection itself were the driver, the researchers reasoned, nearly all infected mice should have gone into early labor. Instead, something about how individual mothers responded to the infection determined the outcome.

When they examined the mice that did deliver early, the pattern became clear. These mothers showed excessive inflammation in the bladder, lower levels of a protective immune protein called interleukin-10 in their blood, and heightened activation of immune T cells compared to infected mothers who carried their pregnancies to term. Critically, the bacterial burden—the actual number of bacteria present—was similar in both groups. The difference lay entirely in the immune response. To test whether this immune imbalance was truly causal, the researchers supplemented some infected mothers with interleukin-10 or prevented T cells from leaving lymph nodes. Both interventions prevented preterm birth, suggesting that restoring immune balance could block the pathway to early labor.

The team then looked at human pregnancies, analyzing immune proteins in the urine of pregnant people with confirmed urinary tract infections. They found the same pattern: cytokines associated with T cell immunity were linked to preterm birth, independent of whether bacteria were actually present in the urine. This alignment between the mouse model and human data strengthens the case that the immune response signature, not the infection itself, is what matters clinically.

The implications are substantial. If specific immune markers can predict which infected pregnant people will deliver early, doctors could identify at-risk mothers before labor begins. More importantly, the findings suggest that treating a UTI during pregnancy might require more than antibiotics. Therapies aimed at restoring immune balance—boosting interleukin-10 or dampening T cell activation—could become part of the standard approach. For now, the research provides a mechanistic framework for understanding a long-observed clinical pattern and points toward biomarkers and interventions that could reshape how pregnancy complications are managed. The next step is translating these discoveries into clinical trials that test whether immune-modulating strategies can prevent preterm birth in human pregnancies.